Ventricular pacing leads to a dilated myopathy in which cell death and myocyte hypertrophy predominate. Because angiotensin II (Ang II) stimulates myocyte growth and triggers apoptosis, we tested whether canine myocytes express the components of the renin-angiotensin system (RAS) and whether the local RAS is upregulated with heart failure. p53 modulates transcription of angiotensinogen (Aogen) and AT 1 receptors in myocytes, raising the possibility that enhanced p53 function in the decompensated heart potentiates Ang II synthesis and Ang II-mediated responses. Therefore, the presence of mRNA transcripts for Aogen, renin, angiotensin-converting enzyme, chymase, and AT 1 and AT 2 receptors was evaluated by reverse transcriptase-polymerase chain reaction in myocytes. Changes in the protein expression of these genes were then determined by Western blot in myocytes from control dogs and dogs affected by congestive heart failure. p53 binding to the promoter of Aogen and AT 1 receptor was also determined. Ang II in myocytes was measured by ELISA and by immunocytochemistry and confocal microscopy. Myocytes expressed mRNAs for all the constituents of RAS, and heart failure was characterized by increased p53 DNA binding to Aogen and AT 1 . Additionally, protein levels of Aogen, renin, cathepsin D, angiotensin-converting enzyme, and AT 1 were markedly increased in paced myocytes. Conversely, chymase and AT 2 proteins were not altered. Ang II quantity and labeling of myocytes increased significantly with cardiac decompensation. In conclusion, dog myocytes synthesize Ang II, and activation of p53 function with ventricular pacing upregulates the myocyte RAS and the generation and secretion of Ang II. Ang II may promote myocyte growth and death, contributing to the development of heart failure. (Circ Res. 2001;88:298-304.) Key Words: pacing Ⅲ myocyte renin-angiotensin system Ⅲ p53 function Ⅲ heart failure Original
M yocyte death and myocyte hypertrophy characterize dilated cardiomyopathy in humans. 1, 2 Cardiomegaly, ventricular dilation, myocyte apoptosis, and myocyte hypertrophy develop with rapid ventricular pacing, [3] [4] [5] mimicking the human disease. Angiotensin (Ang) II is implicated in the activation of several cellular responses, including myocyte apoptosis and hypertrophy. 6 -8 Interference with the systemic and local renin-angiotensin system (RAS) limits myocyte growth and the expansion in cavitary volume, improving ventricular performance and the lifespan of patients with cardiac failure. 9 -11 Experimentally, similar interventions inhibit apoptotic cell death in the stressed myocardium preventing or attenuating decompensation. 12, 13 Rat ventricular myocytes possess the various components of RAS, and an upregulation of renin, Aogen, Ang I, angiotensin-converting enzyme (ACE), Ang II, and AT 1 and AT 2 receptors occurs in myocytes of the overloaded rat heart. 14 -17 Whether canine myocytes synthesize Ang II, influencing directly cellular adaptations via an autocrine mechanism, remains to be demonstrated. This is a relevant issue, because other pathways in the formation of Ang II have been identified in the dog myocardium. 18, 19 Chymostatin-sensitive angiotensin-producing enzyme, ie, heart chymase, has been implicated as the major source of Ang II accumulation in the canine, 18, 19 baboon, 20 and human 21, 22 hearts. These observations tend to minimize the role of ACE in the conversion of Ang I to Ang II in large mammals and raise questions on the existence of a myocyte RAS because of the claimed absence of chymase in this cell population. 18 -22 However, opposite results have also been reported. 23 One of the problems with these findings is that little attention has been given to myocytes even though the entire myocardium or the properties of the interstitial fluid have been analyzed. 18 -25 In view of these uncertainties, the expression of the multiple constituents of RAS was measured at the mRNA and protein levels in myocytes of normal and paced dog hearts. Additionally, p53 function was analyzed because the tumor suppressor transactivates Aogen and AT 1 receptor. 6,7,26 -28 Aogen is the limiting factor in the synthesis of Ang II, 28 and binding to AT 1 conditions myocyte growth and death. 6, 7 Thus, we established whether canine myocytes have the capability of generating Ang II, whether Ang II formation is enhanced in the overloaded ventricle, and whether p53 transcriptional potential correlates with the response of stressed myocytes. Positive results would imply that Ang II plays a critical role in myocyte growth, myocyte death, and the terminal evolution of the failing heart.
Materials and Methods

Ventricular Function
Mongrel dogs were instrumented with corkscrew electrode in the left ventricle (LV) attached to an external pacemaker. 4, 5, 26, 29 Hearts were paced at 210 bpm for 1 (nϭ6) and 3 (nϭ6) weeks and at 240 bpm for an additional week (nϭ7). Control dogs were instrumented but not paced (nϭ7). Protocols were approved by New York Medical College. Cardiac function was measured in conscious dogs with the pacemaker turned off. 26, 29 
Myocyte Isolation
Myocytes were enzymatically dissociated ( Figure 1 ) from 6 control hearts and 4, 4, and 6 hearts paced for 1, 3, and 4 weeks, respectively. 4, 5, 26 Purity of the preparation and the distinction of myocytes from other cells is described in the online data supplement available at http://www.circresaha.org.
Reverse Transcriptase-Polymerase Chain Reaction
Total RNA was extracted with Trizol reagent (Gibco Life Technologies). Total RNA 5 g was reverse transcribed with 200 U of Superscript II reverse transcriptase (RT) (Gibco Life Technologies) according to the supplier protocol. The resulting cDNA was amplified using 1.5 U Taq DNA polymerase (Boehringer Mannheim) as described in the supplier protocol. Sense and antisense primers and polymerase chain reaction (PCR) amplification cycles used for Aogen, renin, chymase, ACE, AT 1 and AT 2 receptors, and ␤-actin are described in the online data supplement. PCR products were separated on a 2% agarose gel.
Electrophoretic Mobility Shift Assay
Oligonucleotides were prepared as recently described. 6,7,26 -28 Nuclear extracts, 40 g, were incubated with 2 L of [ 32 P]ATP-endlabeled probe and subjected to electrophoresis. Control for specificity included the exposure of nuclear extracts to anti-p53, 0.5 g of PAb 240, or an irrelevant antibody, 0.5 g of mouse anti-c-Jun.
Western Blot
Equivalents of 50 to 75 g of proteins were separated by SDS-PAGE, transferred on nitrocellulose membranes, and exposed to mouse anti-rat Aogen, mouse anti-rat renin, mouse monoclonal anti-human cathepsin D, mouse monoclonal anti-rat ACE, 30 mouse monoclonal anti-human chymase, rabbit polyclonal anti-human AT 1 receptor, and rabbit polyclonal anti-rat AT 2 receptor 31 antibodies. Rat kidney and purified human ACE were used as positive controls for ACE. Rat adrenal gland was used as a positive control for AT 2 .
Ang II Labeling
Myocardial sections were fixed in formaldehyde and incubated with Ang II antiserum. 6, 7 Specificity was determined by preabsorption of 10 L of antibody with 0.05 mg of antigen. Nonimmune rabbit serum was used as an additional control. 6, 7 Myocyte cytoplasm was identified by ␣-sarcomeric actin antibody. 6, 7 Ang II-positive myocytes and number of Ang II sites per myocyte profile were measured by confocal microscopy.
Ang II Concentration
Ang II levels in myocytes were obtained by ELISA using the methodology previously described. 9, 27 
Data Analysis
Results are meanϮSD. Autoradiograms were analyzed by an image analyzer. Each set of samples in each gel included all time points after pacing and controls. Statistical significance was determined by Student's t test or Bonferroni method.
An expanded Materials and Methods section can be found in an online data supplement available at http://www.circresaha.org.
Results
Ventricular Hemodynamics
Alterations in cardiac function in this animal model have been described. 4, 5, 26, 27 With 4 weeks of pacing, heart rate increased 42% (PϽ0.001), from 86Ϯ12 to 122Ϯ15 bpm, and mean arterial pressure decreased 18% (PϽ0.01), from 106Ϯ9 to 87Ϯ9 mm Hg. Similarly, LV systolic pressure decreased 24% (PϽ0.001), from 132Ϯ8 to 100Ϯ11 mm Hg, and LV positive dP/dt decreased 48% (PϽ0.001), from 2970Ϯ457 to 1546Ϯ351 mm Hg/s. Conversely, LV end-diastolic pressure increased 333% (PϽ0.001), from 6Ϯ2 to 26Ϯ6 mm Hg. Tachypnea, ascites, pulmonary congestion, and pleural effusion were present in these animals. There were no significant hemodynamic changes at 1 week of pacing, whereas at 3 weeks, LV end-diastolic pressure was increased 133% (PϽ0.01), to 14Ϯ3 mm Hg.
RT-PCR of Aogen, Renin, ACE, Chymase, and AT 1 and AT 2 Receptors
The expression of the components of the local RAS in control and paced canine myocytes was detected by RT-PCR ( Figure  2 ). Four determinations were obtained for each gene. The use of RT-PCR did not permit quantitative measurements of the changes in mRNAs with the duration of pacing. These difficulties in the interpretation of mRNA levels are inherent in this methodology. However, the purpose of this analysis was to document that a myocyte RAS was present at baseline and that ventricular dysfunction and failure with prolonged pacing did not impair the ability of dog myocytes to express these transcripts.
p53 DNA Binding
p53 is implicated in the upregulation of the myocyte RAS, leading to the synthesis and secretion of Ang II. 6,7,28 A gel-retardation assay was performed using oligonucleotides, including the consensus site for p53 binding to the Aogen and AT 1 promoter, respectively. On the basis of the results described above, this assay was restricted to myocytes from control and failing hearts at 4 weeks of pacing, to establish whether a correlation existed between p53 function and RAS activation in the terminal phases of the dilated myopathy. Figure 3A illustrates that the Aogen oligonucleotide resulted in the formation of a p53-shifted complex in nuclear extracts from myocytes of sham-operated and failing dogs. However, the optical density (OD) of the p53 band was increased in cells from paced hearts (controls, ODϭ1Ϯ0.2, nϭ6; paced, ODϭ2.9Ϯ1.1, nϭ6; PϽ0.005). The specificity of the assay was confirmed by demonstrating that the addition of an excess of unlabeled self-oligonucleotide or of a monoclonal p53 antibody to nuclear extracts from paced myocytes opposed the appearance of a p53 band. Conversely, preincubation with an irrelevant antibody did not affect p53 DNA binding. The effects of pacing on p53 binding to the promoter of AT 1 receptor are shown in Figure 3B . Two specific bands were identified, but the OD of the shifted complexes was significantly greater in myocytes from paced hearts (ODϭ1.4Ϯ0.4, nϭ6; paced, ODϭ3.5Ϯ0.8, nϭ6; PϽ0.001).
Western Blot of Aogen, Renin, Cathepsin D, ACE, Chymase, and AT 1 and AT 2 Receptors
The protein levels of the myocyte RAS were analyzed in control and failing hearts at 4 weeks of pacing. Expression of Aogen, renin, and cathepsin D in myocytes is illustrated in Figure 4 . Aogen was represented by 2 bands at 54 and 56 kDa, but the higher molecular-weight protein prevailed (Figure 4A ). Cardiac failure resulted in a 2.5-fold (PϽ0.001) increase in Aogen expression in myocytes, from a baseline OD value of 3.3Ϯ0.7 (nϭ6) to a value of 8.1Ϯ1.6 (nϭ6). Similarly, renin was detected as 2 distinct bands at 36 and 37 kDa, respectively ( Figure 4B ). With pacing, renin increased 3.6-fold (controls, ODϭ1.2Ϯ0.4, nϭ6; paced, ODϭ4.3Ϯ1.1, nϭ6, PϽ0.001), paralleling the changes in Aogen. Myocyte cathepsin D appeared as 3 bands at 52, 43, and 34 kDa ( Figure 4C ). However, the mature form of cathepsin D corresponds to 43 kDa and is the most visible on Western blot. Quantitatively, only the 43-kDa band was measured, because the 52-kDa protein is an inactive precursor, and the 34-kDa protein is an inactive degradation product. Pacing was associated with a 3-fold (PϽ0.001) increase of the active 43-kDa enzyme (controls, ODϭ1.1Ϯ0.3, nϭ6; paced, ODϭ3.3Ϯ0.7, nϭ6).
Two forms of ACE were identified at 134 and 170 kDa ( Figure 5A ). The higher molecular weight reflected the glycosylated enzyme; the other form corresponded to nonglycosylated ACE. Both proteins increased with heart failure. The 134-kDa band increased 1.45-fold (PϽ0.005), and the 170-kDa band increased 1.44-fold (PϽ0.002). In contrast, chymase, detected at 29 kDa, did not change (Pϭ0.28) in nonpaced and paced animals ( Figure 5A ). AT 2 receptor increased 42% ( Figure 5B ) with pacing, but this change was not significant (PϽ0.06). Conversely, AT 1 receptor in myocytes increased significantly, 1.7-fold (PϽ0.001) at 4 weeks after pacing ( Figure 6 ) (controls, ODϭ3.1Ϯ0.75, nϭ6; paced, ODϭ5.4Ϯ0.98, nϭ6).
Data by Western blot were not always consistent with the levels of expression obtained by RT-PCR. These differences reflected the nonquantitative aspects of RT-PCR and the fact that changes in mRNAs are not necessarily identical to those in the quantity of proteins. Conversely, immunoblotting has inherent limitations in the precise identification of the size of each protein. Different molecular weight markers were used to minimize this possibility.
Ang II Quantity in Myocytes
Ang II was measured in left ventricular myocytes by ELISA. Pacing resulted in a 2.2-fold (PϽ0.004) increase in the quantity of Ang II in myocytes (controls, 20Ϯ11 pg/mg protein, nϭ5; paced, 44Ϯ7 pg/mg protein, nϭ5). Two additional approaches were used: quantitative evaluation of the percentage of myocytes labeled by Ang II antibody and measurements of Ang II sites per unit area of myocyte cytoplasm by confocal microscopy. Figure 7A illustrates by green fluorescence the discrete sites of Ang II labeling, and Figure 7B depicts by red fluorescence myocytes stained by ␣-sarcomeric actin. These two images are shown together in Figure 7C ; the fluorescent dots correspond to the localization of Ang II in the myocardium. Myocyte profiles, defined by laminin staining, contained a minimum of 1 to a maximum of 14 stained sites per cell. Preabsorption of the primary Ang II antibody with Ang II resulted in the absence of immunostaining ( Figure 7D) . Similarly, substitution of the Ang II antibody with nonimmune rabbit serum was characterized by the lack of staining in the myocardium (not shown). An average of 180 ventricular myocytes were examined at random in each of 6 nonpaced and 6 paced dogs, for a total of 1086 and 1056 cells in the 2 groups of animals. This analysis demonstrated that 22Ϯ4% and 45Ϯ7% of myocytes were labeled in nonpaced and paced hearts, respectively. Cardiac failure resulted in a 2-fold (PϽ0.001) increase in the fraction of myocytes containing Ang II. Additionally, the number of Ang II-positive sites per mm 2 of myocytes was 2310Ϯ607 and 6285Ϯ659 in control and paced dogs, respectively. The 2.7-fold greater value with pacing was significant (PϽ0.001). The distribution of Ang II-positive dots in labeled cells and the fraction of negative myocytes are shown in Figure 8 . Ang II was increased in all cell categories of paced dogs. Whether the increase in Ang II correlated with an increase in myocyte size with the progression of pacing remains to be investigated.
Discussion
The results of the present study indicate that canine ventricular myocytes expressed the various molecular components of RAS and were capable of forming Ang II. Cathepsin D and chymase were detectable in these cells, pointing to the possibility of the conversion of Aogen to Ang I and Ang I to Ang II through pathways independent from renin and ACE. Surface AT 1 and AT 2 receptors were identified in myocytes. Cardiac failure was characterized by an upregulation of Aogen, renin, cathepsin D, ACE, and Ang II, whereas chymase was not increased; AT 1 receptor protein increased, but the quantity of AT 2 was not significantly altered. p53 function was enhanced in myocytes, leading to activation of the p53-regulated genes Aogen and AT 1 receptor. These observations support the notion that the local synthesis of Ang II may be implicated in myocyte death and cellular hypertrophy in experimental dilated cardiomyopathy.
Ventricular Pacing and Generation of Ang II in Myocytes
Analysis of the local RAS in the dog and baboon heart has been restricted to myocardial samples 18 -20 or examination of interstitial fluid. 24, 25 These investigations have provided significant information concerning the role of the chymase system in the generation of Ang II in the normal and overloaded heart. 18 -20,24,25 Similar findings have been reported in humans, strengthening the contribution of chymase in the formation of Ang II in the nonfailing and failing heart. 21, 22 Although not all studies are in agreement, 23 the major source of chymase was linked to interstitial cells, and ACE was localized to the endothelial cell membrane only. 23 On this basis, myocytes were not identified as a cell population expressing chymase or ACE activity and thereby were assumed of limited importance in the synthesis and secretion of Ang II in the myocardium of large mammals. 18 -25 Results in this study document that canine myocytes contained Ang II. Contrary to expectation, chymase and ACE were detected in these cells, and the upregulation of the myocyte RAS with cardiac failure was associated with increased ACE without changes in chymase. This does not exclude that both enzymes were involved in the generation of Ang II in the overloaded myocytes. Renin mRNA has been previously identified in rat cardiac myocytes, 14 and its expression increases with heart failure. 16 The present data confirm these observations in canine myocytes. Renin can be synthesized directly in cardiac muscle cells, and its formation is enhanced in the decompensated dog heart. Sarcomere stretching in vitro, which mimics diastolic overload in vivo, results in an upregulation of renin 32 and other components of RAS, leading to the production and release of Ang II from the cells. 6, 7 Cathepsin D, which is ubiquitously present in the lysosomes of all cells, 33 was found in myocytes, and a 3-fold increase was measured after ventricular pacing. This aspartyl protease 34 may be implicated in combination with renin in the synthesis of Ang I with pacing. In summary, dog myocytes are most likely implicated in the regulation of the myocardial RAS under normal and pathological states.
Ventricular Pacing and Ang II-Receptor Subtypes
Two isoforms of Ang II receptors, AT 1 and AT 2 , have been identified in neonatal myocytes. 34 With maturation, AT 2 progressively decreases and AT 1 predominates. [35] [36] [37] AT 2 receptors are upregulated in the myocardium after pressure overload or infarction, 17, 38, 39 but their role remains unclear. In neonatal myocytes, Ang II-mediated hypertrophy is potentiated when AT 2 blocking agents are used. 40 Similarly, deletion of the AT 2 gene leads to an abnormal elevation in arterial blood pressure, coupled with alterations in resistance vessels and smooth muscle cell hyperplasia. 41 By autoradiography of the human heart, AT 2 receptors have been found in fibroblasts; AT 2 expression is increased with heart failure, and this may oppose fibroblast proliferation induced by AT 1 -receptor activation. 37 Myocytes show minimal amount of AT 2 at baseline, and this quantity is not affected by cardiac decompensation. 37 In this study, AT 1 and AT 2 were detected in pure preparations of myocytes from nonpaced and paced hearts. The documentation of AT 2 in adult canine myocytes has no precedent. Cardiac failure was characterized by an increase in AT 1 , but the changes in AT 2 were not significant. This differential adaptation suggests that AT 1 receptor activation is implicated in the cellular responses that condition remodeling of the paced ventricle: myocyte apoptosis 5,26 and cellular enlargement. 4 Increases in Ang II and AT 1 receptors with tachycardia may promote hypertrophy 8 or trigger death in myocytes susceptible to growth or apoptotic signals. 6, 7 
Ventricular Pacing and p53
Although stretching and the secretion of Ang II from myocytes may be the immediate consequence of the elevation in left ventricular end-diastolic pressure with pacing, 42 it is more difficult to understand the mechanism by which the local RAS is activated, maintaining the formation of Ang II. p53 binding to the promoter of Aogen and AT 1 receptor was enhanced in the failing heart, resulting in an upregulation of Aogen and AT 1 proteins in myocytes. Because renin and cathepsin D, as well as ACE and chymase, are normally present in canine myocytes, the formation of Aogen may be the limiting factor in the generation of Ang II. Overexpression of p53 in myocytes in vitro enhances transcription of Aogen and AT 1 receptor, leading to the production and release of Ang II. 43 Similarly, sarcomere elongation increases the quantity and functional activity of p53, which are coupled with the induction of multiple p53-regulated genes, including Aogen and AT 1 receptor. 6, 7 p53 binding to the bax promoter is enhanced, and the amount of Bax protein in myocytes increases several fold. 6 Conversely, Bcl-2 is decreased. These cellular responses are inhibited by infection of myocytes with an inactive form of p53. 28 Thus, upregulation of p53 function with pacing may play a critical role in the chronic synthesis of Ang II and Ang II-mediated myocyte hypertrophy and death in this model. 4, 26 
